Biovie Alzheimer’s & Long COVID Research Accepted at 2026 Psychiatry Conference | NewsOut

Biotech and healthcare investors: Biovie, a clinical-stage company developing therapies for neurological and neurodegenerative diseases, announced two research abstracts have been accepted for presentation at the 2026 American College of Psychiatrists annual meeting.

Reporting from the New York Stock Exchange, Jane King explains the studies evaluate the company’s lead drug candidate for Alzheimer’s disease and Long COVID, with presentations scheduled during the February 18–22 conference in Bonita Springs, Florida.

#Biovie
#AlzheimersResearch
#LongCOVID
#ClinicalTrials
#NeurologicalDiseases
#NeurodegenerativeDiseases
#BiotechNews
#MedicalResearch
#DrugDevelopment
#HealthcareInvesting
#JaneKing
#NewsOut